Crossref
journal-article
Elsevier BV
The Lancet (78)
References
27
Referenced
334
- Food and Drug Administration. Reinventing the regulation of cancer drugs: accelerating approval and expanding access. Washington DC: National Performance Review, March 1996.
10.1177/009286159803200105
/ Drug Inf J / Faster access to drugs for serious or life‐threatening illnesses through use of the accelerated approval regulation in the United States by Cocchetto (1998)10.1002/sim.4780130906
/ Stat Med / Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research by Fleming (1994)10.1056/NEJM199304083281409
/ N Engl J Med / Treatment of non‐Hodgkin's lymphoma by Armitage (1993)10.1056/NEJM199309303291402
/ N Eng J Med / A predictive model for aggressive non‐Hodgkin's lymphoma (1993)10.7326/0003-4819-122-4-199502150-00003
/ Ann Intern Med / Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon‐a therapy by Kantarjian (1995)10.1001/jama.1984.03350190024013
/ JAMA / Does response make a difference in patient survival? by Oye (1984)10.1200/JCO.1992.10.6.896
/ J Clin Oncol / Modulation of 5‐fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate (1992)10.1200/JCO.1994.12.5.960
/ J Clin Oncol / Meta‐analysis of randomized trials testing the biochemical modulation of 5‐fluorouracil by methotrexate in metastatic colorectal cancer (1994)10.1200/JCO.1998.16.1.301
/ J Clin Oncol / Efficacy of intravenous continuous infusion of 5‐fluorouracil compared with bolus administration in patients with advanced colorectal cancer (1998)10.1093/jnci/88.5.252
/ J Natl Cancer Inst / Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer (1996){'key': '10.1016/S0140-6736(00)02528-9_bib12', 'series-title': 'WHO Handbook for Reporting results of Cancer Treatment WHO Offset Publication number 48', 'year': '1979'}
/ WHO Handbook for Reporting results of Cancer Treatment WHO Offset Publication number 48 (1979)10.1200/JCO.1983.1.11.710
/ J Clin Oncol / Analysis of survival by tumor response by Anderson (1983)10.1002/(SICI)1097-0258(19961230)15:24<2797::AID-SIM290>3.0.CO;2-V
/ Stat Med / On the relationship between response to treatment and survival time by Buyse (1996)10.2307/2533853
/ Biometrics / Validation of surrogate endpoints in randomized clinical trials by Buyse (1998){'key': '10.1016/S0140-6736(00)02528-9_bib16', 'series-title': 'Proceedings of the Biopharmaceutical Section', 'first-page': '40', 'article-title': 'Validation of surrogate endpoints in multiple randomized clinical trials with failure‐time endpoints', 'author': 'Burzykowski', 'year': '1999'}
/ Proceedings of the Biopharmaceutical Section / Validation of surrogate endpoints in multiple randomized clinical trials with failure‐time endpoints by Burzykowski (1999)10.1093/biostatistics/1.1.49
/ Biostatistics / The validation of surrogate endpoints in meta‐analyses of randomized experiments by Buyse (2000)10.1002/sim.4780110204
/ Stat Med / Statistical validation of intermediate endpoints for chronic diseases by Freedman (1992)10.1002/(SICI)1097-0258(19970715)16:13<1515::AID-SIM572>3.0.CO;2-1
/ Stat Med / Estimating the proportion of treatment effect explained by a surrogate marker by Lin (1997)10.1038/bjc.1994.345
/ Br J Cancer / The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer by Graf (1994)10.1016/S0197-2456(83)80011-7
/ Control Clin Trials / Comparing survival of responders and nonresponders after treatment: a potential source of confusion in interpreting cancer clinical trials by Weiss (1983){'key': '10.1016/S0140-6736(00)02528-9_bib22', 'first-page': '1155', 'article-title': 'Food and Drug Administration requirements for approval of new anticancer drugs', 'volume': '69', 'author': 'Johnson', 'year': '1985', 'journal-title': 'Cancer Treat Rep'}
/ Cancer Treat Rep / Food and Drug Administration requirements for approval of new anticancer drugs by Johnson (1985)10.1002/1097-0142(19801001)46:7<1536::AID-CNCR2820460707>3.0.CO;2-K
/ Cancer / Survival and response to chemotherapy for advanced colorectal adenocarcinoma by Lavin (1980)-
Molenberghs G, Buyse M, Geys H, Renard D, Burzykowski T. Statistical challenges in the evaluation of surrogate endpoints in randomized trials. Stat Med (in press).
(
10.1016/S0197-2456(02)00236-2
) 10.1200/JCO.1993.11.10.1879
/ J Clin Oncol / The benefit of leucovorin‐modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C‐03 by Wolmark (1993)10.1016/S0140-6736(95)90696-7
/ Lancet / Efficacy of adjuvant fluorouracil and folinic acid in colon cancer (1995)10.1200/JCO.1997.15.1.246
/ J Clin Oncol / Controlled trial of fluorouracil and low‐dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer by O'Connell (1997)
Dates
Type | When |
---|---|
Created | 23 years, 1 month ago (July 25, 2002, 10:10 a.m.) |
Deposited | 6 years, 4 months ago (April 28, 2019, 12:21 p.m.) |
Indexed | 1 week, 2 days ago (Aug. 27, 2025, 12:20 p.m.) |
Issued | 25 years, 2 months ago (July 1, 2000) |
Published | 25 years, 2 months ago (July 1, 2000) |
Published Print | 25 years, 2 months ago (July 1, 2000) |
@article{Buyse_2000, title={Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis}, volume={356}, ISSN={0140-6736}, url={http://dx.doi.org/10.1016/s0140-6736(00)02528-9}, DOI={10.1016/s0140-6736(00)02528-9}, number={9227}, journal={The Lancet}, publisher={Elsevier BV}, author={Buyse, Marc and Thirion, Pierre and Carlson, Robert W and Burzykowski, Tomasz and Molenberghs, Geert and Piedbois, Pascal}, year={2000}, month=jul, pages={373–378} }